Table 2.

Adverse Events According to the Common Terminology Criteria for Adverse Events (CTCAE—Version 5)

	Full cohort (n = 70)
Treatment-related deaths, n	0
Patients with adverse events CTCAE ≥ grade 3, n	47 (67%)
Patients with hematotoxicity CTCAE ≥ grade 3, n	31 (44%)
Neutropenia	8 (26%)
Lymphopenia	11 (35%)
Pancytopenia	7 (23%)
Thrombopenia	5 (16%)
Patients with nonhematological adverse events CTCAE ≥ grade 3, n	16 (23%)
Dysgeusia	1 (6%)
Epidural empyema	1 (6%)
GGT elevation	3 (19%)
Hypernatremia	1 (6%)
Lipase elevation	1 (6%)
Nausea	1 (6%)
Seizure	2 (13%)
Transaminase elevation	6 (38%)

GGT, gamma-glutamyltransferase.